Top Tweets for #ASH18RF

over 7 years ago

#ASCO19 Tweeps, people at #ASH18 thought this format of consolidating huge data (all the @ASCO abstracts and talks) was helpful. #ASH18top10 #ASH18VR #ASH18RF #ASH18MT I'll try to work on post-Easter...

almost 8 years ago

#ASH18 #mmsm "Top 5" Myeloma Abstract Picks [updated] #ASH18top10 #ASH18VR #ASH18RF #ASH18MT @DrOlaLandgren @End_myeloma @Rfonsi1 @VincentRK @szusmani @Phari

2

63

32

5

0

1

11

2

0

over 7 years ago

#ASH18top10 - your top 10 picks (at end of meeting) #ASH18VR = @VincentRK tags #ASH18RF = @rfonsi tags #ASH18MT = @mtmdphd tags #ASHaiku18 #ASHsm = social media #LeonardList = @JohnPLeonardMD top abstract list HTO = Hematology Tag Ontology = https://t.co/JtaHtuh6pL

0

1

0

almost 8 years ago

KPD in HOVON EMN Study for RR MM CR 42%, >= VGPR 76%. #ASH18RF

0

2

0

almost 8 years ago

Nearly 1000 pts show we should aim for deep response in AL (bortezomib induction). Goals <10 mg/L, 1/dl) #ASH18RF

0

7

1

0

almost 8 years ago

Sustained MRD negativity at 12 months speaks volumes. Near perfect line to 48 mos even, regardless of Rx #ASH18RF

0

5

3

0

almost 8 years ago

It is worth remembering that the genetics of myeloma change with age. Translocations are less common in the elderly, while hyperdiploidy is more common with advancing age. Accordingly high risk myeloma is less common in the elderly. Not absolute but real #ash18 #MMSM #ASH18RF

Rfonsi1's tweet photo. It is worth remembering that the genetics of myeloma change with age. Translocations are less common in the elderly, while hyperdiploidy is more common with advancing age. Accordingly high risk myeloma is less common in the elderly. Not absolute but real #ash18 #MMSM #ASH18RF https://t.co/sor7FJMtOS

1

10

3

0

almost 8 years ago · San Diego

Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma https://t.co/PPeuRI0EeG via @onclive #ash18rf

0

5

3

0

almost 8 years ago

#ASH18 #mmsm "Top 5" Myeloma Abstract Picks [updated] #ASH18top10 #ASH18VR #ASH18RF #ASH18MT @DrOlaLandgren @End_myeloma @Rfonsi1 @VincentRK @szusmani @Phari

2

63

32

5

0

almost 8 years ago

#ASH18 #mmsm "Top 5" Myeloma Abstract Picks #ASH18VR #ASH18RF #ASH18MT @DrOlaLandgren @End_myeloma @Rfonsi1 @VincentRK @mtmdphd @szusmani

mtmdphd's tweet photo. #ASH18 #mmsm "Top 5" Myeloma Abstract Picks
#ASH18VR #ASH18RF #ASH18MT @DrOlaLandgren @End_myeloma @Rfonsi1 @VincentRK @mtmdphd @szusmani https://t.co/7JnS6quXR9

0

5

2

1

0

almost 8 years ago

Key abstracts, not therapy, nor biology. #ASH18RF 1) Patient preferences in RR MM - PFS and neuropathy 2) Do we really need to collect urines? 3) Why is there such poor quality with bone protection? 4) Biased as mine, 50% attrtition per line of therapy in NDMM Non-SCT

1

2

0

Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰

almost 8 years ago

Critical point. If you say drug A followed later by drug B is probably just as good as A+B, it is incumbent on you to consider the fraction of pts who don't get the opportunity of that second-time point to get drug B. A high rate of attrition. Others have shown too #ASH18RF

@szusmani

almost 8 years ago

The myth that all #mmsm pts get all drugs, save best for last refuted here by ⁦@Rfonsi1 in our abstract showing 50% attrition rate with each line of therapy, major implications in picking best combos in each line! #ASH2018 https://t.co/zDXVBPpnGX #ASH18 ⁦@AtriumHealth⁩

0

15

7

0

8

2

0

almost 8 years ago

My 5 TOP FIVE at ASH 2018. It was hard as great work is being presented. #ASH18RF But here they are: 1) BCMA directed 420 2) MAIA Study 3) KRD vs KRD SCT vs KCD 4) TOURMALINE-MM3 study 5) STORM #mmsm @mtmdphd @VincentRK @szusmani @grpetersen1 @NorthTxMSG @MyelomaTeacher

2

44

16

2

0

almost 8 years ago

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL). #ASH18RF LBA Tue https://t.co/Wo2rkjEIBc

3

7

1

0

almost 8 years ago

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed MM #ASH18RF Tue https://t.co/sH2F0XKDm8

Rfonsi1's tweet photo. Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed MM #ASH18RF Tue https://t.co/sH2F0XKDm8 https://t.co/RApZb8yWOo

2

7

6

0

almost 8 years ago

CASSINI. Rivaroxaban 10 mg once daily reduces risk risk of DVT in patients undergoing cancer therapy #ASH18RF LBA Tuesday https://t.co/bdUWuXyDFK

Rfonsi1's tweet photo. CASSINI. Rivaroxaban 10 mg once daily reduces risk risk of DVT in patients undergoing cancer therapy #ASH18RF LBA Tuesday https://t.co/bdUWuXyDFK https://t.co/nY2FIQH7ov

3

5

2

0

almost 8 years ago

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? Its time to stop collecting urines! #ASH18RF Sunday https://t.co/xbBPRcwPSF

Rfonsi1's tweet photo. Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? Its time to stop collecting urines! #ASH18RF Sunday https://t.co/xbBPRcwPSF https://t.co/CBKt2w2ANE

1

9

7

0